Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers

Doravirine (DOR) is a non‐nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV‐1. Its use in combination with rifapentine (RPT), an antituberculosis (TB) antibiotic, may reduce the exposure of DOR compromising viral suppression in those living with HIV‐1 co‐infected with TB....

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Edwin, Schaefer, Joseph, Zheng, Richard, Zhan, Tingting, Kraft, Walter K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719366/
https://www.ncbi.nlm.nih.gov/pubmed/32407548
http://dx.doi.org/10.1111/cts.12810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719366/
https://www.ncbi.nlm.nih.gov/pubmed/32407548
http://dx.doi.org/10.1111/cts.12810

Ejemplares similares